نتائج البحث

程序性死亡受体 1 / 程序性死亡受体配体 1 抑制剂 联合抗血管生成药物治疗晚期肝细胞癌的临床 研究进展.

• Authors : 江 雪^1,2 ; 葛晓英^1,2; 郑 丹^1,2

• Source: Evaluation & Analysis of Drug-Use in Hospitals of China. 2024, Issue 1, p124-128. 5p.

تفاصيل العنوان

Research Advances of PD-1/PD-L1 Inhibitors Combined with Angiogenesis Inhibitors in Treatment of Advanced Triple-negative Breast Cancer

• Authors : HUANG Shifen; LING Xiaoling

Subjects: advanced triple-negative breast cancer; pd-1/pd-l1 inhibitors; angiogenesis inhibitors

• Source: Zhongliu Fangzhi Yanjiu, Vol 48, Iss 1, Pp 75-81 (2021)

تفاصيل العنوان

Research Progress of Angiogenesis Inhibitors Plus EGFR-TKI in EGFR-mutated Advanced Non-small Cell Lung Cancer

• Authors : Bowen LI; Jianchao XUE; Yadong WANG

Subjects: lung neoplasms; epidermal growth factor receptor; antiangiogenic drugs

• Source: Chinese Journal of Lung Cancer, Vol 25, Iss 8, Pp 583-592 (2022)

تفاصيل العنوان

[Expert consensus on off-label use of small molecule anti-angiogenic drugs in the treatment of metastatic breast cancer].

• Authors : International Medical Society, Chinese Anti-cancer Association; Breast Cancer Group, Branch of Oncologist, Chinese Medical Doctor Association

Subjects: Angiogenesis Inhibitors*/Angiogenesis Inhibitors*/Angiogenesis Inhibitors*/pharmacology ; Angiogenesis Inhibitors*/Angiogenesis Inhibitors*/Angiogenesis Inhibitors*/therapeutic use ; Breast Neoplasms*/Breast Neoplasms*/Breast Neoplasms*/pathology

• Source: Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2022 Jun 23; Vol. 44 (6), pp. 523-530.Publisher: Chinese Medical Association Country of Publication: China NLM ID: 7910681 Publication Model: Print Cited Medium:

تفاصيل العنوان

Current clinical application progress in angiogenesis inhibitors

• Authors : Lu Yu

Subjects: tumor; angiogenesis; angiogenesis inhibitors

• Source: Journal of Shanghai Normal University (Natural Sciences), Vol 47, Iss 1, Pp 132-138 (2018)

تفاصيل العنوان

Research advances on chemotherapy and targeted therapy of pediatric - type low - grade glioma

• Authors : GE Jing-jing; KONG Chen-chen; ZHAO Chuan

Subjects: glioma; antineoplastic combined chemotherapy protocols; angiogenesis inhibitors

• Source: Chinese Journal of Contemporary Neurology and Neurosurgery, Vol 24, Iss 9, Pp 706-711 (2024)

تفاصيل العنوان

[Chinese expert consensus on antiangiogenic drugs for advanced non-small cell lung cancer (2020 Edition)].

• Authors : Expert Committee on Vessel Targeted Therapy of Chinese Society of Clinical Oncology; Expert Committee on Non-small Cell Lung Cancer of Chinese Society of Clinical Oncology; Expert Group on Antiangiogenic Drugs for Non-small Cell Lung Cancer of Chinese Society of Clinical Oncology

Subjects: Angiogenesis Inhibitors*/Angiogenesis Inhibitors*/Angiogenesis Inhibitors*/therapeutic use ; Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/drug therapy ; Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/pathology

• Source: Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2020 Dec 23; Vol. 42 (12), pp. 1063-1077.Publisher: Chinese Medical Association Country of Publication: China NLM ID: 7910681 Publication Model: Print Cited Medium:

تفاصيل العنوان

中药抑制肝细胞癌血管生成的作用机制.

• Authors : 李香香¹; 王 振²; 杨 星¹

• Source: Journal of Clinical Hepatology / Linchuang Gandanbing Zazhi. Jul2024, Vol. 40 Issue 7, p1477-1485. 9p.

تفاصيل العنوان

晚期肝细胞癌转化治疗的挑战与思考.

• Authors : 卢实春¹

• Source: Journal of Clinical Hepatology / Linchuang Gandanbing Zazhi. Sep2024, Vol. 40 Issue 9, p1738-1740. 3p.

تفاصيل العنوان

Curative Effect of EGFR-TKIs with Anti-angiogenic Drugs as the Treatment for Patients with Advanced EGFR-mutant Non-small Cell Lung Cancer：a Meta-analysis

• Authors : LI Yong, LONG Yong, ZHAO Chong, ZHANG Guanqing, SU Yanhe

Subjects: carcinoma, non-small-cell lung; angiogenesis inhibitors; epidermal growth factor receptor tyrosine kinase inhibitors

• Source: Zhongguo quanke yixue, Vol 25, Iss 08, Pp 1007-1013 (2022)

تفاصيل العنوان